



CLAIMS

1. An oligomeric compound comprising a modified oligonucleotide consisting of 16 to 20 linked nucleosides and having a nucleobase sequence comprising at least 16, at least 17, at least 18, at least 19, or 20 contiguous nucleobases of SEQ ID NO: 1124, wherein the modified oligonucleotide has a nucleobase sequence that is at least 90% complementary to the nucleobase sequence of SEQ ID NO: 1 or SEQ ID NO: 2 when measured across the entire nucleobase sequence of the modified oligonucleotide, wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified internucleoside linkage, wherein the modified sugar moiety is selected from a bicyclic sugar moiety, a 2'-MOE sugar moiety or a 2'-OMe sugar moiety, and wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.
2. An oligomeric compound comprising a modified oligonucleotide consisting of 16 to 20 linked nucleosides and having a nucleobase sequence comprising at least 16, at least 17, at least 18, at least 19, or 20 contiguous nucleobases complementary to an equal length portion of nucleobases 9198-9222 of SEQ ID NO: 2, wherein the modified oligonucleotide comprises at least one modification selected from a modified sugar moiety and a modified internucleoside linkage, wherein the modified sugar moiety is selected from a bicyclic sugar moiety, a 2'-MOE sugar moiety or a 2'-OMe sugar moiety, and wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.
3. The oligomeric compound of claim 1 or 2, wherein the modified oligonucleotide has a nucleobase sequence that is at least 95% or 100% complementary to the nucleobase sequence of SEQ ID NO: 1 or SEQ ID NO: 2 when measured across the entire nucleobase sequence of the modified oligonucleotide.
4. The oligomeric compound of any of claims 1-3, wherein the bicyclic sugar moiety comprises a 4'-2' bridge, wherein the 4'-2' bridge is selected from -CH₂-O-; and -CH(CH₃)-O-.
5. The oligomeric compound of any of claims 1-4, wherein each internucleoside linkage is independently selected from a phosphodiester internucleoside linkage or a phosphorothioate internucleoside linkage.
6. The oligomeric compound of any of claims 1-5, wherein the modified oligonucleotide comprises at least one modified nucleobase.
7. The oligomeric compound of claim 6, wherein the modified nucleobase is a 5-methylcytosine.
8. The oligomeric compound of any of claims 1-7, wherein the modified oligonucleotide consists of:
 - a) 18-20 linked nucleosides; or
 - b) 20 linked nucleosides.
9. The oligomeric compound of any of claims 1-8, wherein the oligomeric compound comprises a conjugate group.
10. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 1124), or a salt thereof.

11. The modified oligonucleotide of claim 10, which is the sodium salt or the potassium salt.
12. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 1124).

13. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation: ${}^m\text{C}_{\text{es}}\text{A}_{\text{eo}}\text{G}_{\text{eo}}\text{A}_{\text{eo}}\text{T}_{\text{eo}}\text{G}_{\text{eo}}\text{T}_{\text{ds}}\text{T}_{\text{ds}}{}^m\text{C}_{\text{ds}}\text{A}_{\text{ds}}\text{T}_{\text{ds}}{}^m\text{C}_{\text{ds}}\text{T}_{\text{ds}}{}^m\text{C}_{\text{ds}}\text{T}_{\text{ds}}\text{T}_{\text{ds}}{}^m\text{C}_{\text{eo}}\text{A}_{\text{es}}{}^m\text{C}_{\text{es}}\text{A}_{\text{e}}$ (SEQ ID NO: 1124), wherein:

A = an adenine nucleobase,

${}^m\text{C}$ = a 5-methylcytosine nucleobase,

G = a guanine nucleobase,

T = a thymine nucleobase,

e = a 2'-MOE sugar moiety,

d = a 2'-deoxyribose sugar moiety,

s = a phosphorothioate internucleoside linkage, and

o = a phosphodiester internucleoside linkage.

14. A population of oligomeric compounds of any of claims 1-9 or 13, or a population of modified oligonucleotides of any of claims 10-12, wherein all of the phosphorothioate internucleoside linkages of the modified oligonucleotide are stereorandom.
15. A pharmaceutical composition comprising the oligomeric compound of any of claims 1-9 or 13, the modified oligonucleotide of any of claims 10-12, the population of oligomeric compounds of claim 14, or the population of modified oligonucleotides of claim 14, and a pharmaceutically acceptable diluent.
16. The pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable diluent is artificial CSF (aCSF) or phosphate-buffered saline (PBS).
17. The pharmaceutical composition of claim 16, wherein the pharmaceutical composition consists or consists essentially of the modified oligonucleotide or oligomeric compound and aCSF.
18. The pharmaceutical composition of claim 16, wherein the pharmaceutical composition consists or consists essentially of the modified oligonucleotide or oligomeric compound and PBS.
19. The pharmaceutical composition of claim 16, wherein the pharmaceutical composition consists or consists essentially of the population of modified oligonucleotides or population of oligomeric compounds and aCSF.
20. The pharmaceutical composition of claim 16, wherein the pharmaceutical composition consists or consists essentially of the population of modified oligonucleotides or population of oligomeric compounds and PBS.